# Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma

> **NCT04998669** · PHASE2 · RECRUITING · sponsor: **Juan P. Alderuccio, MD** · enrollment: 100 (estimated)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **DRUG:** Loncastuximab tesirine
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT04998669
- **Lead sponsor:** Juan P. Alderuccio, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-02-11
- **Primary completion:** 2027-08-01
- **Final completion:** 2030-08-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04998669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04998669, "Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04998669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*